These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26343594)

  • 1. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.
    Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
    J Psychiatr Res; 2015 Oct; 69():50-6. PubMed ID: 26343594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.
    Lee SY; Chen SL; Chang YH; Chen SH; Chu CH; Huang SY; Tzeng NS; Wang CL; Lee IH; Yeh TL; Yang YK; Lu RB
    J Affect Disord; 2012 May; 138(3):295-300. PubMed ID: 22326841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.
    Chen SL; Lee SY; Chang YH; Chen SH; Chu CH; Tzeng NS; Lee IH; Chen PS; Yeh TL; Huang SY; Yang YK; Lu RB; Hong JS
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):656-64. PubMed ID: 22730040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
    Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ
    Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
    Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
    Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR; Arabzadeh S; Zeinoddini A; Khalili Z; Rezaei F; Mohammadinejad P; Ghaleiha A; Akhondzadeh S
    Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
    Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
    Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
    Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
    Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.